PMV Pharmaceuticals Announces Promising Updated Data From the PYNNACLE Phase 2 Pivotal Trial of Rezatapopt Monotherapy in Patients With TP53 Y220C-Mutated…

PMV Pharmaceuticals, Inc. (PMVP) filed an SEC Form 8-K — Other Events. Exhibit 99.1 PMV Pharmaceuticals Announces Promising Updated Data From the PYNNACLE Phase 2 Pivotal Trial of Rezatapopt Monotherapy in Patients With TP53 Y220C-Mutated Advanced Solid Tumors • 48% confirmed overall response rate (ORR) with a 10.4-month median duration of response

Event · Clinical / regulatory
Product
rezatapopt
Milestone
topline data
Indication
platinum-resistant/refractory ovarian cancer

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 20, 2026, 9:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 20, 2026, 9:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$PMVP
Bullish
high confidence
Mentioned
$PMVP
Relevance
9/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PMVPBullishMed
01

Why it matters

The 8-K provides updated investigator-assessed efficacy for the pivotal Phase 2 portion, including ORR and duration in platinum-resistant/refractory ovarian cancer, and reiterates an NDA submission plan for accelerated approval in 1Q 2027.

02

Market read

Traders can update biotech risk models immediately using the newly disclosed ORR/duration figures and the stated 1Q 2027 NDA timeline.

03

What to watch

Safety tolerability in a larger, registrational context and the strength of the FDA accelerated-approval package (including confirmatory strategy) could be the gating items despite the positive ORR.

Relevance 9/10Novelty 8/10Timing: after-hours filing today, with NDA planned for first quarter 2027

Background

PMV Pharma’s rezatapopt is a p53 Y220C reactivator in the PYNNACLE Phase 1/2 trial, with Phase 2 designed as a registrational expansion basket across multiple tumor cohorts.

Company-level read

Ticker impact

$PMVPBullishHigh confidence
Context

PMV Pharmaceuticals filed an 8-K with updated PYNNACLE Phase 2 results for rezatapopt, including 48% ORR and planned NDA submission in 1Q 2027.

Expected impact

Likely upward pressure as traders price in higher odds of accelerated approval and near-term NDA filing execution.

Evidence & confidence

The filing discloses new, specific efficacy endpoints (ORR, duration, disease control) plus a concrete first-quarter 2027 NDA plan, which are direct decision inputs for biotech risk/reward.

Market effects

Strengthens sentiment for p53 Y220C targeted oncology and small-molecule reactivators, potentially improving read-through for similar precision oncology programs.

Primarily US biotech sentiment, with conference presentation in Europe adding incremental visibility.

Moderate global relevance via ENA 2026 late-breaking presentation and regulatory pathway expectations.

Counterpoint

Single-arm basket data can overstate durability and generalizability; investors may discount ORR without randomized confirmation and longer follow-up.

Key entities

  • PMV Pharmaceuticals, Inc.

    Nasdaq-listed precision oncology company reporting updated PYNNACLE Phase 2 data for rezatapopt.

  • Rezatapopt (PC14586)

    Small-molecule p53 reactivator targeting the TP53 Y220C mutation.

  • PYNNACLE Phase 2

    Registrational single-arm expansion basket trial with ovarian, lung, breast, endometrial, and other solid tumor cohorts.

  • ENA 2026

    EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics where the data were presented as a late-breaking oral.

Related articles

$PMVPMed

PMV Pharmaceuticals 3Q 2026: EPS ($0.52) — 10-Q Summary

PMV Pharmaceuticals reported a wider net loss of $34.37M in Q3 2026, with EPS at ($0.52), due to warrant remeasurement loss and offering costs. The company completed enrollment for a Phase 2 trial of rezatapopt and plans to submit an NDA in Q1 2027. Cash reserves totaled $108.5M, expected to last into Q1 2028.

$PMVPMedAI 8/10

PMV Pharmaceuticals Reports Q3 2026 Results, $108.5M in Cash and Securities

PMV Pharmaceuticals reported a Q3 2026 net loss of $34.4M, with $108.5M in cash. It expects cash to last into Q1 2028. The company completed enrollment for its Phase 2 ovarian cancer trial and plans to submit a rezatapopt NDA in Q1 2027. Research and development expenses were $16.1M, with general and administrative expenses at $4.0M. The company appointed new board members and a chief commercial officer.

$PMVPMed

PMV Pharmaceuticals Reports Third Quarter 2026 Financial Results and Corporate

PMV Pharmaceuticals, Inc. (PMVP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PMV Pharmaceuticals Reports Third Quarter 2026 Financial Results and Corporate Highlights • Pivotal Phase 2 rezatapopt PYNNACLE data to be featured in late-breaking oral presentation at ENA 2026 • Announced closing of oversubscribed $50 million public offering of sec

$PMVPMed

PMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights

PMV Pharmaceuticals (Nasdaq: PMVP) reported Q2 2026 results and clinical updates. Enrollment for the Phase 2 monotherapy primary analysis in its PYNNACLE trial for rezatapopt in TP53 Y220C ovarian cancer is complete. The company plans an NDA for accelerated approval in Q1 2027. Cash, cash equivalents and marketable securities were $79.4M at June 30, 2026, with net loss $18.1M.